PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; imlunestrant for breast cancer, tafasitamab for follicular lymphoma, atezolizumab for thymic carcinoma, retifanlimab for anal canal squamous cell carcinoma, and tagraxofusp for blastic plasmacytoid dendritic cell neoplasm

International Journal of Clinical Oncology 2026 Open access

Read full text

Authors: Noriomi Matsumura

DOI: 10.1007/s10147-025-02955-3

Cited by: 0

References: 5

Fields of Study & Subjects

HER2/EGFR in Cancer Research Biosimilars and Bioanalytical Methods Cancer Immunotherapy and Biomarkers

References 5